Restoring osimertinib sensitivity in EGFR-mutant NSCLC: the role of anlotinib in modulating Wnt/β-catenin/YAP pathways
Abstract
< 0.01), with decreased expression of EGFR, PD-L1, YAP, and β-catenin. These findings suggest that high PD-L1 expression promotes osimertinib resistance through activation of YAP and Wnt/β-catenin, and that anlotinib combined with osimertinib can reverse resistance by restoring GSK3β activity, activating the Hippo pathway, and inhibiting β-catenin signaling.
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
Hippo pathway signaling and YAP/TAZ
Cancer Immunotherapy and Biomarkers
Publication details
- Journal / source
- American Journal of Cancer Research
- Volume
- 16
- Issue
- 1
- Pages
- 291–313
- Publication date
- 1 January 2026
- Language
- EN